Elixirr has, as expected, reported a strong set of H1 results with sales up +3.2% vs H2 2019 (+18% vs. H1 2019) and adj. EBITDA margins up from 28.1% to 33.6% despite COVID-19. EBITDA increased by 23%. The outlook is positive, with record monthly revenue achieved in June and then again in July and management is confident it will continue to progress with its objectives for the remainder of the year and into the future. We make no changes to our forecasts and reiterate our view that the entrep
15 Sep 2020
Elixirr - Record sales in June and again in July
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Elixirr - Record sales in June and again in July
Elixirr International Plc (ELIX:LON) | 570 57 1.8% | Mkt Cap: 269.5m
- Published:
15 Sep 2020 -
Author:
Guy Hewett -
Pages:
8
Elixirr has, as expected, reported a strong set of H1 results with sales up +3.2% vs H2 2019 (+18% vs. H1 2019) and adj. EBITDA margins up from 28.1% to 33.6% despite COVID-19. EBITDA increased by 23%. The outlook is positive, with record monthly revenue achieved in June and then again in July and management is confident it will continue to progress with its objectives for the remainder of the year and into the future. We make no changes to our forecasts and reiterate our view that the entrep